VYVGART Hytrulo

Product NDC
73475-3102
11-digit product format
734753102
Labeler code
73475
Product ID
73475-3102_a2607d4b-76e8-4004-94c2-190fdc8593fb
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
efgartigimod alfa and hyaluronidase (human recombinant)
Dosage form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Labeler
argenx US
Application
BLA761304
Marketing category
BLA
Marketing start
2023-06-20
Substance
EFGARTIGIMOD ALFA; HYALURONIDASE (HUMAN RECOMBINANT)
Active strength
180; 2000 mg/mL; U/mL
Pharmacologic classes
Endoglycosidase [EPC], Glycoside Hydrolases [CS], Neonatal Fc Receptor Blocker [EPC], Neonatal Fc Receptor Blockers [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product
Yes
Brand name base
VYVGART Hytrulo
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
EFGARTIGIMOD ALFA180 mg/mL
HYALURONIDASE (HUMAN RECOMBINANT)2000 U/mL

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 2 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
961YV2O515Internal UNII lookup
743QUY4VD8Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 4 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
2639951Internal RxNorm lookup
2639957Internal RxNorm lookup
2712083Internal RxNorm lookup
2712088Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
7104d9e5-9910-47f5-9a93-741ac50f43b6Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
fba5a780-b52d-4964-b662-1526b044aec4Product name120260127
64196b0b-840e-435b-8afa-0b0e9d9cea99Product name120251024
4b151d8d-9b47-43df-bccb-6abc1c4e7194Product name120250331
d745a796-f789-46a3-afa3-79dead22a863Product name120250331
00bb4496-246c-4f2c-910a-2b2783035958Product name120231025
e0c39752-98ba-4b96-a1e0-1fe4c0365ed0Product name120220720
bd11614e-4776-4a92-aaca-2bcbb5f710edProduct name120210115
0c6eff6a-9a1e-468b-b9ca-6bc864c2e8cbProduct name120200925
6d78c268-2e9d-bd45-9f2d-965fd0e582caProduct name220200323
b914e981-d6dc-4748-bd51-accd6b85b817Product name120190618
4597a7a9-59c8-4eb4-b516-4f26fa3dfe4bProduct name120170804
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
1681bc73-b05f-12c3-1075-382ae39f449cProduct name120140508

FDA-Initiated Inactive NDC Indexing#

Related label table
Related label
These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
73475-3102-3VYVGART Hytrulo1 in 1 CARTONINJECTION, SOLUTION112
73475-3102-3VYVGART Hytrulo5.6 mL in 1 VIAL, SINGLE-DOSEINJECTION, SOLUTION5.612

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
73475-3102-3ML - Milliliter73475-3102f0e0fbea-e904-4a87-b610-8ef15d5a136b12023-07-06

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
73475-3102VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)) INJECTION, SOLUTION [ARGENX US]7Current NDC, 2 package rows20250418_7104d9e5-9910-47f5-9a93-741ac50f43b6.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
VYVGART HytruloEFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)argenx US7104d9e5-9910-47f5-9a93-741ac50f43b62026-07-15Warnings, Adverse reactionsExact identifier
application number: BLA761304
ndc (product): 73475-3102

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761304Vyvgart Hytruloefgartigimod alfa and hyaluronidase-qvfc351(a)Rx2026-09-01

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
2712083efgartigimod alfa 1,000 MG / hyaluronidase-qvfc 10,000 UNT in 5 ML Prefilled SyringePSN7104d9e5-9910-47f5-9a93-741ac50f43b612
2639951efgartigimod alfa-hyaluronidase-qvfc 1008 MG / 11,200 UNT in 5.6 ML InjectionPSN7104d9e5-9910-47f5-9a93-741ac50f43b612
2712088VYVGART Hytrulo 1,000 MG / 10,000 UNT in 5 ML Prefilled SyringePSN7104d9e5-9910-47f5-9a93-741ac50f43b612
2639957VYVGART Hytrulo 1008 MG / 11,200 UNT in 5.6 ML InjectionPSN7104d9e5-9910-47f5-9a93-741ac50f43b612
27120885 ML efgartigimod alfa-qvfc 200 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Prefilled Syringe [Vyvgart Hytrulo]SBD7104d9e5-9910-47f5-9a93-741ac50f43b612
26399575.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Injection [Vyvgart Hytrulo]SBD7104d9e5-9910-47f5-9a93-741ac50f43b612
27120835 ML efgartigimod alfa-qvfc 200 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Prefilled SyringeSCD7104d9e5-9910-47f5-9a93-741ac50f43b612
26399515.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML InjectionSCD7104d9e5-9910-47f5-9a93-741ac50f43b612
2712083efgartigimod alfa 1,000 MG / hyaluronidase-qvfc 10,000 UNT per 5 ML Prefilled SyringeSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2639951efgartigimod alfa-hyaluronidase-qvfc 1008 MG / 11,200 UNT per 5.6 ML InjectionSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2639951efgartigimod alfa-qvfc 1008 MG / hyaluronidase-qvfc 11,200 UNT per 5.6 ML InjectionSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2712088Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase-qvfc 1,000 MG / 10,000 UNT) per 5 ML Prefilled SyringeSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2639957Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase-qvfc 1008 MG / 11,200 UNT) per 5.6 ML InjectionSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2639957Vyvgart Hytrulo 1008 MG / 11,200 UNT per 5.6 ML InjectionSY7104d9e5-9910-47f5-9a93-741ac50f43b612

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
73475-3102-3734753102031 VIAL, SINGLE-DOSE in 1 CARTON (73475-3102-3) / 5.6 mL in 1 VIAL, SINGLE-DOSE2023-06-20NoNoCurrent